The Behavioral Economist
Behavioral finance, growth, small-cap, fund holdings

NanoViricides Incorporated: A Biotech Innovator Bound Only By Its Own Ambition

As 2013 approaches its inevitable end, the investment world has begun to debate the presence of a "biotechnology bubble". That is to say, a discussion has begun with the objective of concluding whether or not the biotechnology industry has become an over-priced market fueled by its own momentum. If it has, the potential end result is an industry wide crash which will adversely affect companies and shareholders alike. However, this is unlikely. Sure, similar yearlong run-ups in other industries have been met with inevitable demise (most notably the housing crash and the dotcom boom) but biotechnology is different. Biotechnology is an industry in a class all its own. It is fueled by innovation and genius. Genius innovations, in the medical...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details